Kinase inhibitor salts and compositions thereof

A method for treating thyroid cancer, renal cell carcinoma or hepatocellar carcinoma comprising orally administering to a patient in need of such therapy an oral dosage form comprising a therapeutically effective amount of cabozantinib lauryl sulfate salt and at least one pharmaceutically acceptable excipient wherein the amount of cabozantinib lauryl sulfate contained within the oral dosage form is equivalent to about 5 mg to about 200 mg of cabozantinib free base.